Weekly belimumab treatment was safe and effective and superior to placebo for reducing disease activity over 52 weeks in patients who were hypocomplementemic and anti-dsDNA positive.
Researchers investigated whether patients with SLE receive lipid testing and statin prescriptions comparably with patients with diabetes.
Certain clinical and serological markers were predictive of future incident proteinuria in patients with systemic lupus erythematosus.
Systemic lupus erythematosus is among the top 20 leading causes of death in women between the ages of 5 and 64 years in the United States.
Investigators suggest several mechanisms for the contribution of poverty to high mortality rates in patients with systemic lupus erythematosus.
Researchers compared the quality of care received by patients with systemic lupus erythematosus in 2 settings within the same academic institution.
The frequency of metabolic syndrome among patients with SLE was approximately 45%.
Blisibimod was effective in patients with SLE in terms of steroid reduction, decreased proteinuria, and improvement in serological markers.
Researchers examined differences in the ability to get pregnant in women with systemic lupus erythematosus and rheumatoid arthritis.
Ofatumumab was a well-tolerated, safe, and effective alternative to rituximab for B cell depletion therapy.
